Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 2 1Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Skin Neoplasms 1Sarcoma 1Melanoma 1Glioma 1Central Nervous System Neoplasms 1Carcinoma, Squamous Cell 1Carcinoma, Basal Cell 1Breast Neoplasms 1Brain Neoplasms 1

Interventions

Temozolomide 38Radiotherapy 22Radiosurgery 22Radiation 11Magnetic Resonance Spectroscopy 11Irinotecan 11Cyclophosphamide 11Etoposide 10Surgical Procedures, Operative 9Erlotinib Hydrochloride 9Carmustine 9pembrolizumab 8Filgrastim 8Carboplatin 8Bevacizumab 7Vincristine 6Sorafenib 6O(6)-benzylguanine 6Nivolumab 6Flucytosine 6Aminolevulinic Acid 6temsirolimus 5sargramostim 5Vorinostat 5Trastuzumab 5Topotecan 5Imatinib Mesylate 5Granulocyte Colony-Stimulating Factor 5Everolimus 5cediranib 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Brain Neoplasms × tozuleristide × Clear all
NCT02462629 2023-02-21

Study of BLZ-100 in Pediatric Subjects With CNS Tumors

Blaze Bioscience Inc.

Phase 1 Completed
29 enrolled
CNS

Brain Neoplasms, Central Nervous System Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡